← Scoopfeeds — Intelligent news, curated.
Novo Nordisk (NVO) lifts 2026 outlook as obesity drug demand remains strong
business

Novo Nordisk (NVO) lifts 2026 outlook as obesity drug demand remains strong

Yahoo Finance · May 6, 2026, 10:35 AM · Also reported by 4 other sources

Novo Nordisk (NVO) lifts 2026 outlook as obesity drug demand remains strong

Read full story on Yahoo Finance → More top stories

Also covered by

Investing.com Novo Nordisk lifts 2026 outlook as Wegovy drives growth; shares surge Bloomberg Tech Uber Delivers Upbeat Outlook in Sign of Strong US Demand Bloomberg Markets CVS Boosts Outlook for 2026 After Aetna Profits Increase Investing.com GEO Group surges 20% on strong earnings beat and raised outlook

More in business

CoinDesk
Memecoin trades carry rare 'seven-leg' parlay odds, BONK's Nom says at Consensus
Decrypt
Morning Minute: Crypto Majors Rally, Oil Falls on Renewed Peace Hopes
Bloomberg Markets
US Treasury Signals No Change on Auction Sizes Into 2027
Forbes
The Struggle To Redraw Eurasia’s Energy Map
Bloomberg Markets
Poland Holds Rates as Iran Energy Shock Stokes Inflation
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop